Form 4: Regeneron Director Michael Brown Acquires Equity

Regeneron Pharmaceuticals Director Michael S. Brown reported the acquisition of restricted stock units and non-qualified stock options, effective January 2, 2026.

Summary

• Michael S. Brown, a Director at Regeneron Pharmaceuticals, Inc. (REGN), reported changes in his beneficial ownership.
• On January 2, 2026, Mr. Brown acquired 155 shares of Common Stock in the form of time-based vesting restricted stock units (RSUs) at a price of $0.0.
• Following this acquisition, his direct beneficial ownership of Common Stock increased to 1,703 shares.
• He also acquired 1,962 Non-Qualified Stock Options with an exercise price of $772.76, exercisable starting January 2, 2026, and expiring on January 2, 2036.
• A portion of these stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date.
• Mr. Brown also indirectly beneficially owns 5,000 shares through a SLAT (trust for immediate family, beneficial ownership disclaimed) and 6,162 shares through another Trust.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is generally a positive sign of alignment between management and shareholder interests, without any negative implications.

Positives

• Director Michael S. Brown acquired 155 restricted stock units, aligning his interests with shareholders.
• The grant of 1,962 non-qualified stock options provides a long-term incentive for the director, with an exercise price of $772.76.

Future Outlook

The filing details future equity grants and their vesting schedules, indicating a long-term incentive structure for the director. The stock options will become exercisable partially on the date of the Issuer's first annual meeting of shareholders following the grant date, and the remainder on the first anniversary of the grant date.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the pharmaceutical and biotechnology industry, where stock options and restricted stock units are commonly used to align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• The equity grants to Director Michael S. Brown, consisting of restricted stock units and non-qualified stock options, are consistent with typical compensation structures for non-employee directors in large-cap pharmaceutical companies.
• Companies like Pfizer, Merck, and Johnson & Johnson frequently utilize similar equity-based incentives to attract and retain experienced board members, linking their compensation to company performance and long-term stock appreciation.

Related Party Transactions

• 5,000 shares are held in a SLAT (Spousal Lifetime Access Trust) for the benefit of the reporting person's immediate family members, with the reporting person's spouse as trustee. The reporting person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value.

Next Steps

• The acquired restricted stock units will vest over time.
• The non-qualified stock options will become exercisable partially on the date of the Issuer's first annual meeting of shareholders following the grant date, and the remainder on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a director and does not contain information that would significantly alter the investment thesis for Regeneron Pharmaceuticals. It reflects standard corporate governance and compensation practices, suggesting stability rather than a catalyst for a 'buy' or 'sell' decision. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Regeneron Pharmaceuticals, REGN, Michael S. Brown, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership